Home Page >
News and press releases >
News archive >
Mucovac2 HIV vaccine trial starts enrolment
Mucovac2 HIV vaccine starts enrolment
6 December 2011
Mucovac2
is a phase I clinical trial to assess the safety and immunogenicity
of three HIV CN54gp140 immunisations administered through the
intramuscular, intranasal and intravaginal routes in healthy female
volunteers. After various setbacks it has at last started
recruitment at both sites, St Georges in London, and York.
Participants are recruited through advertising at the sites and
through the Help Make
History website.
There is an urgent need to develop methods to
prevent HIV infection and the aim of this study is to assess the
safety and immunogenicity of a new potential HIV vaccine. An HIV
vaccine is widely considered to be one of the most effective and
sustainable ways of reducing the rate of new infections.
At present, it is not clear which way of
giving an HIV vaccine is best at stimulating the immune system and
preventing the virus from being acquired through sex. The vaccine
being tested (CN54gp140) has previously been shown to be safe when
given to a small number of women intravaginally.
Mucovac2 will look at giving the same
potential HIV vaccine in four different combinations using three
different routes – intramuscularly, intranasally and intravaginally
– and in three different concentrations. As well as assessing the
safety of a new potential HIV vaccine we will also assess how well
the vaccine stimulates the body’s immune system by testing blood in
the laboratory.
Help Make History is an MRC-funded network of
healthy volunteers who would, in principle, be willing to
participate in HIV prevention trials. More information can be found
at the Help Make History website.
Further information
